European Medical Solutions (STU:AS00) 6-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AS00 European Medical Solutions STU:AS00
51 GF Score
Price €3.60
GF Value €7.49
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is European Medical Solutions 6-Month Share Buyback Ratio?

European Medical Solutions STU:AS00 +9.76% 51 6-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates STU:AS00 with a GF Score™ of 51/100 and a GF Value™ of €7.49 (Possible Value Trap). The stock has 2 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. European Medical Solutions's current 6-Month Share Buyback Ratio was 0.00%.


European Medical Solutions  (STU:AS00) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


European Medical Solutions 6-Month Share Buyback Ratio Related Terms


STU:AS00 vs VRTX, REGN, RVMD: 6-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, European Medical Solutions's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


European Medical Solutions 6-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, European Medical Solutions's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where European Medical Solutions's 6-Month Share Buyback Ratio falls into.


STU:AS00
51GF Score
European Medical Solutions STU:AS00
6-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

European Medical Solutions 6-Month Share Buyback Ratio Calculation

European Medical Solutions's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Jun. 2025 ) - Shares Outstanding (EOP) (Dec. 2025 )) / Shares Outstanding (EOP) (Jun. 2025 )
=(4.232 - 4.232) / 4.232
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 6-Month Share Buyback Ratio of 0.00 mean?
European Medical Solutions (STU:AS00) has a 6-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for European Medical Solutions and its competitors.
Is European Medical Solutions' 6-Month Share Buyback Ratio too high?
European Medical Solutions' current 6-Month Share Buyback Ratio is 0.00. Overall, European Medical Solutions has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' 6-Month Share Buyback Ratio compare to VRTX and REGN?
European Medical Solutions' 6-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Share Buyback Ratio for a Biotechnology company?
A good 6-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 6-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Share Buyback Ratio mean?
A high 6-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for European Medical Solutions and its competitors. European Medical Solutions's current 6-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
Based on GuruFocus' analysis, European Medical Solutions (STU:AS00) is currently considered Possible Value Trap. The stock's GF Value™ is €7.49, compared to a current price of €3.60 — trading 51.9% below its estimated fair value. The current 6-Month Share Buyback Ratio is 0.00. European Medical Solutions' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Share Buyback Ratio calculated?
6-Month Share Buyback Ratio is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current 6-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is European Medical Solutions (STU:AS00) Overvalued in 2026?

Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued. The current stock price of €3.60 is trading 51.9% below its estimated GF Value™ of €7.49. GuruFocus considers European Medical Solutions to be Possible Value Trap.

Key valuation signals for STU:AS00:

  • 6-Month Share Buyback Ratio: 0.00
  • GF Value™: €7.49 vs. price of €3.60 (51.9% below fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


European Medical Solutions Business Description

Other Exchanges ALEMS:Belgium
Address 7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
51GF Score

Get the complete analysis for STU:AS00

6-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.60
Price
€7.49
GF Value